COLORECTAL CANCER DIAGNOSTICS VIA DETECTION OF TISSUE-SPECIFIC EXTRACELLULAR NANO-VESICLES

The development of methods for effective diagnosis and monitoring of colorectal cancer (CRC) treatment is one of the basic scientific problem. The circulating plasma contains extracellular nanovesicles (EVs) secreted mainly by blood and endothelial cells. The minor fraction of plasma EVs is produced by cells of various tissues, including cells of the intestinal epithelium. The biochemical composition of such vesicles should have tissue-specific features. Presented study was aimed to identify surface markers of EVs secreted by intestinal epithelium cells and to assess the possibility of isolating and quantification of such vesicles for the diagnosis of CRC. The cell cultures (HCT-116, HT-29, COLO-320, HuTu-80, SW837), plasma of CRC patients and healthy donors were used in the study. The methods of nanoparticle tracking analysis (NTA), atomic force microscopy (AFM), dot-blotting and flow cytometry were applied for EVs characterization. With the original technology of immunosorption we have demonstrated an increased amount of CLRN3, GAL4 and Meprin A, i.e. positive EVs in plasma of CRC patients  comparing to healthy donors. Based on the quantitative analysis of such EVs, new methods of diagnostics and monitoring of CRC therapy can be developed.

1. Puzanov D.P., Polovinkin V.V., Puzanova I.A. Colorectal cancer screening. current techniques and recommendations review. Innovative medicine of Kuban. 2018; no.1, pp.58-64. (in Russ.).

2. Bénard F, Barkun AN, Martel F, von Renteln D. Systematic review of colorectal cancer screening guidelines for average-risk adults: Summarizing the current global recommendations. World J Gastroenterol. 2018; 7:124–138.

3. Stanciu J, Tariman J. Liquid Biopsy: A Tool for the Diagnostic and Prognostic Evaluation of Cancers. Clin J Oncol Nurs. 2020; 24:19-21.

4. Brahmer A. et al. Platelets, endothelial cells and leukocytes contribute to the exercise-triggered release of extracellular vesicles into the circulation. J Extracell Vesicles. 2019 May 28; 8(1):1615820. DOI: 10.1080/20013078.2019.1615820

5. Larssen P. et al. Tracing Cellular Origin of Human Exosomes Using Multiplex Proximity Extension Assays. Mol Cell Proteomics. 2017; 16:1547–1547.

6. Kobayashi M. et al. A Pilot Trial to Quantify Plasma Exosomes in Colorectal Cancer Screening from the International Collaborative Study between Chile and Japan. Digestion. 2018; 98:270–274.

7. Wang L, Duan W, Yan S, Xie Y. et al. Circulating long non-coding RNA colon cancer-associated transcript 2 protected by exosome as a potential biomarker for colorectal cancer. Biomed Pharmac other. 2019 May 14; 113:108758. DOI: 10.1016/j.biopha.2019.108758

8. Ogata-Kawata H. et al. Circulating Exosomal microRNAs as Biomarkers of Colon Cancer. PLoS One. 9, 2014; e92921.

9. Zambalova E.A. et al. Exosomal proteases in colorectal cancer. Advances in Molecular Oncology. 2018; no.5(4), pp.117-126. (In Russ.).

10. Lewis JM. et al. Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient Blood. ACS Nano. 2018; 12:3311–3320.

11. Zhang Y, Mi X, Tan X. et al. Recent Progress on Liquid Biopsy Analysis using Surface-Enhanced Raman Spectroscopy. Theranostics. 2019; 9:491–525.

12. Santasusagna S. et al. Proteomic Analysis of Liquid Biopsy from Tumor-Draining Vein Indicates that High Expression of Exosomal ECM1 Is Associated with Relapse in Stage I-III Colon Cancer. Transl. Oncol. 2018; 11:715–721.

13. Theodoraki M-N, Matsumoto A, Beccard I, et al. CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients’ plasma as potential noninvasive biomarkers of disease activity. Oncoimmunology. 2020; 9:1747732.

14. Ferrone S, Whiteside TL. Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids. HNO. 2020; 68:100-105.

15. Théry C, Amigorena S, Raposo G. et al. Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids. Curr Protoc Cell Biol. 2006; 30, 3.22.1-3.22.29.

16. www.proteinatlas.org. The Human Protein Athlas.

17. www.uniprot.org. UniProt Consortium.

18. www.exocarta.org. ExoCarta.

19. Linnekamp JF. et al. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. Cell Death Differ. 2018; 25:616–633.

20. Théry C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018; 23(7):1535750. DOI:10.1080/20013078.2018.1535750

21. Mannavola F. et al. Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now? Front Oncol. 2019 Jun 19; 9:521. DOI: 10.3389/fonc.2019.00521. eCollection 2019.

22. Takano Y. et al. Circulating exosomal microRNA-203 is associated with metastasis possibly via inducing tumor-associated macrophages in colorectal cancer. Oncotarget. 2017; 8:78598–78613.

23. WANG X. et al. Investigation of the roles of exosomes in colorectal cancer liver metastasis. Oncol Rep. 2015; 33:2445–2453.

24. Samsonov R.B. et al. Diagnostic value of exosomal miRNAs for colorectal cancer. Koloproktologia. 2018; no.2(64), pp.25-31. (In Russ.).

25. Lee C-H, Im E-J, Moon P-G еt al. Discovery of a diagnostic biomarker for colon cancer through proteomic profiling of small extracellular vesicles. BMC Cancer. 2018; 18:1058.